The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York.
Coronavirus
Covid-19
Cystic fibrosis
SARS-CoV2
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
19
07
2021
revised:
03
02
2022
accepted:
16
02
2022
pubmed:
9
3
2022
medline:
3
6
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
People with cystic fibrosis (pwCF) may be at risk of complications from COVID-19 but the impact of COVID-19 on pwCF remains unknown. We conducted a multicenter retrospective cohort study to assess the impact of the COVID-19 pandemic first wave on pwCF in the New York metropolitan area (NY) from March 1, 2020 to August 31, 2020. Objectives were to determine (1) the prevalence of COVID-19 by PCR and IgG antibody testing, (2) the clinical characteristics of COVID-19, (3) delay in routine outpatient care, and (4) the effect on anxiety and depression in pwCF. There were 26 COVID-19 cases diagnosed by PCR or antibody testing among the study cohort of 810 pwCF. The prevalence of COVID-19 by PCR (1.6%) and IgG antibody (12.2%) testing was low. 58% of cases were asymptomatic and 82% were managed at home. 8% were hospitalized and 1 person died. 89% of pwCF experienced delay in care. The prevalence of anxiety increased from 43% baseline to 58% during the pandemic (P<0.01). In post-hoc analysis, the proportion of patients with diabetes (38% versus 16%, P<0.01) and pancreatic insufficiency (96% versus 66%, P<0.01) were higher while CFTR modulator use was lower (46% versus 65%, P = 0.05) in pwCF who tested positive for COVID-19. The prevalence of COVID-19 among pwCF in NY during the pandemic first wave was low and most cases were managed at home. CFTR modulators may be protective. PwCF experienced delay in routine care and increased anxiety.
Sections du résumé
BACKGROUND
People with cystic fibrosis (pwCF) may be at risk of complications from COVID-19 but the impact of COVID-19 on pwCF remains unknown.
METHODS
We conducted a multicenter retrospective cohort study to assess the impact of the COVID-19 pandemic first wave on pwCF in the New York metropolitan area (NY) from March 1, 2020 to August 31, 2020. Objectives were to determine (1) the prevalence of COVID-19 by PCR and IgG antibody testing, (2) the clinical characteristics of COVID-19, (3) delay in routine outpatient care, and (4) the effect on anxiety and depression in pwCF.
RESULTS
There were 26 COVID-19 cases diagnosed by PCR or antibody testing among the study cohort of 810 pwCF. The prevalence of COVID-19 by PCR (1.6%) and IgG antibody (12.2%) testing was low. 58% of cases were asymptomatic and 82% were managed at home. 8% were hospitalized and 1 person died. 89% of pwCF experienced delay in care. The prevalence of anxiety increased from 43% baseline to 58% during the pandemic (P<0.01). In post-hoc analysis, the proportion of patients with diabetes (38% versus 16%, P<0.01) and pancreatic insufficiency (96% versus 66%, P<0.01) were higher while CFTR modulator use was lower (46% versus 65%, P = 0.05) in pwCF who tested positive for COVID-19.
CONCLUSIONS
The prevalence of COVID-19 among pwCF in NY during the pandemic first wave was low and most cases were managed at home. CFTR modulators may be protective. PwCF experienced delay in routine care and increased anxiety.
Identifiants
pubmed: 35256307
pii: S1569-1993(22)00044-3
doi: 10.1016/j.jcf.2022.02.012
pmc: PMC8858720
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e176-e183Informations de copyright
Copyright © 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflicts of interest.
Références
J Clin Med. 2020 Nov 10;9(11):
pubmed: 33182847
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
Acta Biomed. 2020 Sep 07;91(3):e2020035
pubmed: 32921729
J Cyst Fibros. 2021 Jul;20(4):566-577
pubmed: 34016559
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34376550
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115128
pubmed: 32777699
Am J Physiol Lung Cell Mol Physiol. 2020 Sep 1;319(3):L408-L415
pubmed: 32668165
J Cyst Fibros. 2020 May;19(3):355-358
pubmed: 32376098
J Cyst Fibros. 2020 Nov;19(6):872-874
pubmed: 32828701
Gut. 2003 Aug;52(8):1159-64
pubmed: 12865275
Dis Markers. 2021 Jan 6;2021:8810196
pubmed: 33532006
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Eur Respir Rev. 2020 Mar 20;29(155):
pubmed: 32198216
PLoS One. 2014 Jan 10;9(1):e78583
pubmed: 24427261
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Cyst Fibros. 2020 Nov;19(6):868-871
pubmed: 33183965
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
Respir Med. 2020 Aug - Sep;170:106062
pubmed: 32843180
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
J Cyst Fibros. 2021 Mar;20(2):372-373
pubmed: 33549520
J Cyst Fibros. 2020 Nov;19(6):880-887
pubmed: 32768311
Cureus. 2020 Jul 16;12(7):e9218
pubmed: 32821569
Br J Pharmacol. 2013 Jun;169(3):477-92
pubmed: 23488800
Front Med (Lausanne). 2020 Jun 09;7:307
pubmed: 32582746
J Infect Dis. 2021 Jul 15;224(2):188-195
pubmed: 34086923
J Cyst Fibros. 2021 Mar;20(2):198-204
pubmed: 33384222